MSH3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with PARP inhibitors and platinum drugs
Details for Australian Patent Application No. 2011202823 (hide)
International Classifications
Event Publications
30 June 2011 Complete Application Filed
Priority application(s): 61/442,192 12.02.11 US
30 August 2012 Application Open to Public Inspection
Published as AU-A-2011202823
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2011202824-Systems and methods for detecting and geo-locating hazardous refuse
2011202822-Computerized Transaction Bargaining System And Method
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser